294 related articles for article (PubMed ID: 22165970)
1. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.
Kono SA; Heasley LE; Doebele RC; Camidge DR
Curr Cancer Drug Targets; 2012 Feb; 12(2):107-23. PubMed ID: 22165970
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.
Crinò L; Metro G
Eur Respir Rev; 2014 Mar; 23(131):79-91. PubMed ID: 24591665
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiogenesis in squamous non-small cell lung cancer.
Piperdi B; Merla A; Perez-Soler R
Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.
Shikada Y; Yonemitsu Y; Koga T; Onimaru M; Nakano T; Okano S; Sata S; Nakagawa K; Yoshino I; Maehara Y; Sueishi K
Cancer Res; 2005 Aug; 65(16):7241-8. PubMed ID: 16103075
[TBL] [Abstract][Full Text] [Related]
6. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
7. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
9. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
[TBL] [Abstract][Full Text] [Related]
13. PVT1 Promotes Angiogenesis by Regulating miR-29c/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway in Non-Small-Cell Lung Cancer (NSCLC).
Mao Z; Xu B; He L; Zhang G
Med Sci Monit; 2019 Jul; 25():5418-5425. PubMed ID: 31326971
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor signaling in non-small-cell lung cancer.
Semrad TJ; Mack PC
Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.
Giatromanolaki A; Koukourakis MI; Sivridis E; O'Byrne K; Cox G; Thorpe PE; Gatter KC; Harris AL
Clin Cancer Res; 2000 May; 6(5):1917-21. PubMed ID: 10815916
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer.
Slodkowska J; Sikora J; Roszkowski-Sliz K; Radomyski A; Androsiuk W
Anal Quant Cytol Histol; 2000 Oct; 22(5):398-402. PubMed ID: 11064816
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
Salgia R
Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
[TBL] [Abstract][Full Text] [Related]
20. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
